NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis $33.14 +0.97 (+3.02%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$32.35▼$34.0950-Day Range$22.57▼$33.1452-Week Range$16.95▼$49.50Volume1.09 million shsAverage Volume1.40 million shsMarket Capitalization$2.73 billionP/E RatioN/ADividend YieldN/APrice Target$43.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Beam Therapeutics alerts: Email Address Beam Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside31.3% Upside$43.50 Price TargetShort InterestBearish14.65% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 13 Articles This WeekInsider TradingSelling Shares$1.48 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.68) to ($4.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.92 out of 5 starsMedical Sector656th out of 936 stocksBiological Products, Except Diagnostic Industry105th out of 154 stocks 3.2 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 6 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Beam Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.65% of the outstanding shares of Beam Therapeutics have been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 2.20%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BEAM. Previous Next 3.0 News and Social Media Coverage News SentimentBeam Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Beam Therapeutics this week, compared to 5 articles on an average week.Search Interest15 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows10 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,481,928.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($4.68) to ($4.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -18.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -18.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyNvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.To see Porter Stansberry's new AI prediction go here now. About Beam Therapeutics Stock (NASDAQ:BEAM)Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More BEAM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BEAM Stock News HeadlinesJuly 4, 2024 | insidertrades.comAmy Simon Sells 502 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) StockJune 29, 2024 | insidertrades.comInsider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells 60,000 Shares of StockJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 26 at 1:49 AM | tmcnet.comSkyWater Announces Enhanced Capabilities with Multibeam's First in Industry High Productivity Multicolumn E-Beam Lithography SystemJuly 25 at 10:50 AM | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Shares Gap Up to $27.05July 25 at 6:27 AM | msn.comBeam Therapeutics Stock Earns RS Rating Jump To 85July 24 at 9:43 AM | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Now Covered by Analysts at HC WainwrightJuly 24 at 9:41 AM | markets.businessinsider.comCRISPR Therapeutics Nears 52-Week Low. Time to Buy?July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 24 at 9:41 AM | baystreet.caHot Stocks Tips: Viasat, Beam Therapeutics, and HIMSJuly 24 at 8:23 AM | investorplace.comTrade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40July 23, 2024 | msn.comBeam Therapeutics gains as H.C. Wainwright starts at BuyJuly 22, 2024 | investorplace.com3 Gene Editing Stocks Shaping the Future of MedicineJuly 20, 2024 | ca.finance.yahoo.comBEAM Aug 2024 22.500 putJuly 19, 2024 | ca.finance.yahoo.comBeam Therapeutics Inc. (BEAM.MX)July 15, 2024 | globenewswire.comBeam Therapeutics Announces Transition of Chief Financial OfficerJuly 9, 2024 | investorplace.comThe 3 Most Undervalued Gene Editing Stocks to Buy in July 2024July 9, 2024 | investorplace.com3 Stocks With the Potential to 10X Your MoneySee More Headlines Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees436Year Founded2017Price Target and Rating Average Stock Price Target$43.50 High Stock Price Target$80.00 Low Stock Price Target$20.00 Potential Upside/Downside+31.3%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,530,000.00 Net Margins-37.33% Pretax Margin-36.95% Return on Equity-15.46% Return on Assets-9.86% Debt Debt-to-Equity RatioN/A Current Ratio5.99 Quick Ratio5.99 Sales & Book Value Annual Sales$377.71 million Price / Sales7.22 Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book2.75Miscellaneous Outstanding Shares82,310,000Free Float78,854,000Market Cap$2.73 billion OptionableOptionable Beta1.87 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. John M. Evans M.B.A. (Age 46)CEO & Director Comp: $1.11MDr. Giuseppe Ciaramella Ph.D. (Age 55)President Comp: $933.2kMs. Terry-Ann Burrell M.B.A. (Age 47)CFO & Treasurer Comp: $711.15kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D.Co-FounderDr. Alexis Komor Ph.D.Co-FounderDr. Manmohan Singh Ph.D.Chief Technology OfficerDr. Gopi Shanker Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsIntellia TherapeuticsNASDAQ:NTLAReplimune GroupNASDAQ:REPLEditas MedicineNASDAQ:EDITAlloVirNASDAQ:ALVRSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 556,035 shares on 7/26/2024Ownership: 9.265%Bank of New York Mellon CorpSold 2,319 shares on 7/26/2024Ownership: 0.349%Liontrust Investment Partners LLPBought 80,000 shares on 7/26/2024Ownership: 0.097%Baillie Gifford & Co.Sold 128,754 shares on 7/25/2024Ownership: 0.758%Krilogy Financial LLCBought 17,734 shares on 7/22/2024Ownership: 0.062%View All Insider TransactionsView All Institutional Transactions BEAM Stock Analysis - Frequently Asked Questions How have BEAM shares performed this year? Beam Therapeutics' stock was trading at $27.22 at the beginning of the year. Since then, BEAM shares have increased by 21.7% and is now trading at $33.14. View the best growth stocks for 2024 here. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($1.21) earnings per share for the quarter, beating analysts' consensus estimates of ($1.42) by $0.21. Beam Therapeutics's revenue was down 69.4% on a year-over-year basis. Does Beam Therapeutics have any subsidiaries? Beam Therapeutics subsidiaries include Blink Therapeutics Inc.. When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Beam Therapeutics' top institutional shareholders include ARK Investment Management LLC (9.27%), Sumitomo Mitsui Trust Holdings Inc. (2.70%), Baillie Gifford & Co. (0.76%) and Bank of New York Mellon Corp (0.35%). Insiders that own company stock include Fmr Llc, John M Evans, Giuseppe Ciaramella, Christine Bellon, Terry-Ann Burrell and Amy Simon. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS) and Akoustis Technologies (AKTS). This page (NASDAQ:BEAM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAM Stock Alerts